MEDTRONIC'S STENT TRIAL SEEN AS POTENTIAL CATALYST

Banc of America Securities recently reiterated a "buy" rating and $62 target price on Medtronic, saying results for the company's Endeavor III stent trial could provide a catalyst for the stock. "We believe that the favorable in-segment late loss data from Endeavor II increase the likelihood that Endeavor III will meet its primary endpoint of in-segment late loss," Banc of America said.

Forbes (http://www.forbes.com/technology/sciences/2005/09/19/medtronic-stents-guidant-0919markets03.html?partner=rss) (http://www.forbes.com/technology/sciences/2005/09/19/medtronic-stents-guidant-0919markets03.html?partner=rss)

(http://www.forbes.com/technology/sciences/2005/09/19/medtronic-stents-guidant-0919markets03.html?partner=rss)